Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies. However, disease progression and relapse remain a major challenge for the clinical management of paediatric angiosarcoma. Comprehensive genomic profiling of these rare tumours using high-throughput sequencing technologies may improve patient stratification and identify actionable biomarkers for therapeutic intervention. Here, we describe the clinical, histopathological, immunohistochemical and molecular profile of a novel and precision medicine-informed case where a KHDRBS1-NTRK3 fusion determined by next-generation sequencing-based comprehensive genomic profiling led to complete and sustained remission (clinical and radiological response) in an otherwise incurable disease. Our patient represents the first paediatric angiosarcoma harbouring a targetable NTRK3 fusion in the literature and demonstrates the first example of targeting this alteration in angiosarcoma using larotrectinib, an NTRK inhibitor. Clinical and radiological remission was achieved in under two months of therapy, and the patient is currently in complete remission, 4 month after stopping larotrectinib therapy, which was given over 17 months with only mild side effects reported. Therefore, this remarkable case exemplifies the true essence of precision-based care by incorporating conventional pathology with the why, when, and how to test for rare oncogenic drivers and agnostic biomarkers in paediatric angiosarcoma.

[1]  Si Li,et al.  Characterization of NTRK gene fusion events in solid tumors among Chinese patients. , 2021 .

[2]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[3]  S. Bielack,et al.  Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  K. Bencardino,et al.  Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  E. Lander,et al.  The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research , 2019, Nature Medicine.

[6]  J. Sicklick,et al.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.

[7]  C. Antonescu,et al.  A novel group of spindle cell tumors defined by S100 and CD34 co‐expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes , 2018, Genes, chromosomes & cancer.

[8]  Jessica L. Davis,et al.  The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas , 2018, Cancer.

[9]  D. Orbach,et al.  Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report , 2018, Virchows Archiv.

[10]  A. Drilon,et al.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.

[11]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[12]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[13]  C. Antonescu,et al.  Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma , 2017, The American journal of surgical pathology.

[14]  Ryohei Katayama,et al.  Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers , 2017, Molecular Cancer Therapeutics.

[15]  Narasimhan P. Agaram,et al.  Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors , 2016, The American journal of surgical pathology.

[16]  C. Mackall,et al.  Current approach to pediatric soft tissue sarcomas. , 2009, The oncologist.

[17]  N. Sebire,et al.  Angiosarcoma of skull base in a 1-year-old child--a case report. , 2009, International journal of pediatric otorhinolaryngology.

[18]  K. Thornton,et al.  Pediatric soft tissue sarcomas. , 2008, The Surgical clinics of North America.

[19]  A. Ferrari,et al.  Malignant vascular tumors in children and adolescents: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. , 2002, Medical and pediatric oncology.

[20]  M. Skup Neurotrophins : evolution of concepts on rational therapeutic approaches , 2018 .

[21]  S. Skaper Neurotrophic Factors: An Overview. , 2018, Methods in molecular biology.

[22]  M. Chao,et al.  Trk receptors. , 2014, Handbook of experimental pharmacology.

[23]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[24]  D. C. Henckel,et al.  Case report. , 1995, Journal.